Cassava Sciences, Inc. (SAVA) |
|
17.09 -0.72 (-4.04%)
|
09-26 15:27 |
|
Open: |
17.6 |
Pre. Close: |
17.81 |
|
High:
|
18.15 |
Low:
|
17.09 |
|
Volume:
|
358,246 |
Market Cap:
|
717(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 2:52:04 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 23.66 One year: 26.35 |
| Support: |
Support1: 16.54 Support2: 13.76 |
| Resistance: |
Resistance1: 20.26 Resistance2: 22.55 |
| Pivot: |
19.13  |
| Moving Average: |
MA(5): 17.75 MA(20): 19.64
MA(100): 21.78 MA(250): 27.2 |
| MACD: |
MACD(12,26): -0.6 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 4.7 %D(3): 5.3 |
| RSI: |
RSI(14): 34.9 |
| 52-week: |
High: 50.77 Low: 16.54 |
| Average Vol(K): |
3-Month: 960 (K) 10-Days: 694 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SAVA ] has closed above bottom band by 14.1%. Bollinger Bands are 9.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.91 - 18.01 |
18.01 - 18.1 |
|
Low:
|
17.05 - 17.18 |
17.18 - 17.3 |
|
Close:
|
17.62 - 17.81 |
17.81 - 17.99 |
|
Company Description |
|
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. |
Headline News |
Wed, 20 Sep 2023
Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Sold by SG ... - MarketBeat
Mon, 18 Sep 2023
Cassava Sciences Announces Positive Interim Safety Review of ... - BioSpace
Wed, 13 Sep 2023
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease - Yahoo Finance
Thu, 07 Sep 2023
Noteworthy Thursday Option Activity: ABNB, SAVA, DG - Nasdaq
Wed, 06 Sep 2023
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences - Yahoo Finance
Thu, 24 Aug 2023
Premarket Mover: Cassava Sciences Inc (SAVA) Up 11.94% - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
42 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
6 (%) |
|
% Held by Institutions
|
28.9 (%) |
|
Shares Short
|
13,340 (K) |
|
Shares Short P.Month
|
11,430 (K) |
Stock Financials |
|
EPS
|
-2.09 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.28 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-28.8 |
|
Return on Equity (ttm)
|
-45.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-1.63 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.29 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-76 (M) |
|
Levered Free Cash Flow
|
-48 (M) |
Stock Valuations |
|
PE Ratio
|
-8.27 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
4.03 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-9.54 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
